Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company that develops targeted therapies for mast cell driven diseases. Its primary product candidate is briquilimab, a monoclonal antibody engineered to block stem cell factor from binding to the CD117 receptor, thereby depleting mast cells in tissues such as the skin and lungs. The company's development pipeline focuses on treating conditions including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics designs its therapeutic candidates for adult patients who suffer from these chronic inflammatory disorders, particularly individuals whose symptoms remain uncontrolled by standard antihistamines or other existing medical treatments.

The enterprise maintains its corporate headquarters and principal executive offices in Redwood City, California, and is incorporated under the laws of Delaware. It holds global rights to briquilimab through a worldwide licensing agreement with Amgen. The organization conducts multiple clinical-stage evaluation programs, targeting disease populations across the United States and European nations including France, Germany, Italy, Spain, and the United Kingdom.

Summary of the business section of Jasper Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“of December 31, 2025, we employed 22 full-time employees.”